It is certainly important to have a data package that contains compounds showing good in vitro potency and good potency and efficacy in an in vivo model(s). However, if this is the full extent of the licensing data package then the harsh reality is that your program is highly unlikely to achieve a licensing deal [...] Read more »
Inside Big Pharma Licensing: Merck Opens Up About Partnering & How To Get The Ball Rolling (Complimentary Webinar)
OracleBio would like to highlight a forthcoming, complimentary, webinar sponsored by Merck (hosted by Elsevier), which may be of interest to those companies wishing to gain a better perspective of what’s required for a successful licensing deal with large Pharma. The webinar will include talks from a number of individuals from within Merck including: a [...] Read more »
Large Pharma change their stance
A number of the large Pharmaceutical companies have changed tack recently and moved from a highly speculative “more shots on goal” approach within R&D towards a more risk-adverse “clinical validity” approach. The former approach involved pushing numerous compounds (often sub-optimal) forward towards Phase I and II clinical trials with the idea of providing early clinical [...] Read more »
Looking for a licencing deal with Large Pharma? If so, it’s time to start thinking Biomarkers…
In a move reflecting the changes seen within all major pharmaceutical companies, Merck and Co. recently changed their “Areas of Interest” page on their website to highlight the importance of a robust translational biomarker strategy when looking for an in-licencing deal. The document (http://www.merck.com/licensing/areas_of_interest.pdf) now contains the a footnote at the bottom of pages 14-17 [...] Read more »